Change in fair
value of
derivative asset - - (81) -
Other income
(expense), net (3) 922 12 964
--------- --------- --------- ---------
Loss before
provision for
income taxes (5,732) (4,912) (15,260) (16,934)
Provision for
income taxes - - - -
--------- --------- --------- ---------
Net loss
attributable to
Vaccinex, Inc.
common
stockholders $ (5,732) $ (4,912) $ (15,260) $ (16,934)
========= ========= ========= =========
Comprehensive loss $ (5,732) $ (4,912) $ (15,260) $ (16,934)
========= ========= ========= =========
Net loss per share
attributable to
Vaccinex, Inc.
common
stockholders,
basic and diluted $ (2.83) $ (15.25) $ (8.85) $ (59.95)
========= ========= ========= =========
Weighted-average
shares used in
computing net loss
per share
attributable to
Vaccinex, Inc.
common
stockholders,
basic and diluted 2,026,920 322,153 1,724,088 282,467
========= ========= ========= =========
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/551b0bc4-4495-4a65-aa21-a96daddf079e
(END) Dow Jones Newswires
November 18, 2024 08:30 ET (13:30 GMT)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。